New York Genome Center Inc

“Nygc board members eli casdin, anthony evnin, thomas maniatis, and nancy thornberry have a business relationship, either directly or indirectly, through kallyope, inc., a biotechnology company developing oral therapeutics against metabolic, neurological, and gastrointestinal diseases. Nygc has not conducted any business with kallyope, inc.”

“Organization members as of december 31, 2024, the center had a total of 13 members, consisting of ten institutional founding members and three associate members. The institutional founding members are the following recognized academic, medical, and research institutions: (1) cold spring harbor laboratory, (2) cornell university/weill cornell medicine, (3) memorial sloan-kettering cancer center, (4) icahn school of medicine at mount sinai, (5) new york-presbyterian hospital, (6) new york university, school of medicine, (7) northwell health, (8) rockefeller university (9) the research foundation of state university of new york, on behalf of stony brook university, and (10) the trustees of columbia university in the city of new york. Associate members: (1) american museum of natural history, (2) hospital for special surgery, and (3) hackensack meridian health.”

“Organization members - decision making each institutional founding member appoints one representative to serve on nygc's board of directors. The board of directors also includes the scientific director/ceo and independent directors appointed by the board. Decisions requiring board approval include the admission of new members, changes to the mission, certificate of incorporation, and bylaws, appointment or removal of the chairperson of the board and the scientific director, and adoption of certain policies and procedures. The board also reviews and approves the annual operating budget. Management has the ability to enter into business arrangements and contracts, including financing arrangements, and has the discretion to make certain decisions without formal board approval.”

“Form 990 review the form 990 is prepared by an independent public accounting firm, utilizing information provided by management. Upon receipt of the draft form 990, management, including the chief financial officer, general counsel, and the scientific director & ceo, review the form. Prior to filing, management presents the form 990 to the audit committee of the board for review and comment. Prior to filing, management also provides the form 990 to the entire board of directors.”

“Conflict of interest policy & review nygc requires all interested persons (defined as board members, officers, and key employees) to disclose conflicts of interest as required by the conflict of interest policy. Nygc follows a procedure for obtaining such disclosures annually. Any potential conflicts of interest disclosed by board members or officers must be reviewed by the board. If an interested person has a potential conflict of interest, he or she may present information relevant to the conflict of interest or underlying transaction at a board or committee meeting, but after such presentation, he/she shall leave the meeting during the discussion of, and vote on, the transaction or arrangement that creates the potential conflict of interest.”

“Compensation review and approval for the organization's top management official, please refer to schedule j narratives for the process of determining compensation. For 2024, nygc hired an independent, outside compensation consultant to perform an analysis of senior management's total compensation. The review showed that the compensation paid to members of senior management was reasonable. The compensation committee of the board (which is composed of independent board members) met at a committee meeting held in january 2024 and approved the 2024 compensation to be paid to senior management. The committee documented its actions in written meeting minutes. The senior management team did not receive merit increases in 2024.”

“Document availability nygc's governing documents, conflict of interest policy, and financial statements are available upon request.”

“In 2024, tom maniatis, phd., scientific director & ceo, was employed by an unrelated entity and leased to nygc to devote 80% of his time and effort to serve as nygc's scientific director and ceo, an officer of the corporation, and an associate member of nygc's faculty, with responsibility for overseeing nygc's research programs and for undertaking such other activities as nygc's board of directors requested from time to time. Dr. Maniatis devoted 20% of his time to his duties at the unrelated entity, where he maintained a laboratory and conducted independent, investigator-initiated research projects.”

“The new york genome center (nygc) is an independent non-profit scientific research institution dedicated to collaborative genomic research. Nygc's mission is to advance genomic science to drive novel biomedical discoveries and transform patient care through precision medicine. Nygc's areas of focus include the development of computational and experimental genomic methods and disease-focused research to further the understanding of the genetic basis of cancer, neurodegenerative disease, and neuropsychiatric disease. The nygc team, led by evnin family scientific director and ceo, tom maniatis, phd, includes associate and core faculty members who hold joint appointments at leading academic institutions. The center brings together outstanding thought leaders from ten founding & three associate member institutions, as well as 95 affiliate scientific members, to engage in collaborative research. Convening talent and expertise from multiple top-tier scientific and medical institutions in the new york area and beyond, nygc has created a highly collaborative scientific ecosystem and community resource that is more than the sum of its parts. Nygc also provides researchers with access to state-of-the-art genomic infrastructure (e.g., a high-performance computing infrastructure, software, and next-generation sequencing instruments), as well as technology innovation know-how and expertise. Nygc has the following key objectives: (i) leading and contributing to intellectually vibrant research collaborations in the academic and scientific communities in new york city, across the united states, and around the world, fostering innovation and knowledge exchange; (ii) recruiting and retaining diverse, world-class scientific talent to lead the organization's research and technology development programs; (iii) supporting research conducted by the institutional founding members, other academic, research, and medical institutions, as well as the biotechnology and pharmaceutical industry, to advance nygc's scientific research mission; (iv) developing innovative experimental and computational genomic methods based on the research and sequencing activities conducted by nygc for the broader benefit of the research community; (v) improving human health through genomic research that drives novel biomedical discoveries; (vi) providing training to the academic, research, and technology development communities; (vii) creating a workplace environment that is welcoming and fair to all, where every individual feels valued and respected, regardless of race, ethnicity, gender, sexual orientation, physical disability, age, religion, or veteran status, and (viii) carrying out activities ancillary to these objectives.”

“Nygc is committed to advancing genomic science to drive novel biomedical discoveries and transform patient care through precision medicine. Research and faculty nygc maintains a strong commitment to recruiting outstanding faculty with broad expertise in disease genomics, computational and machine learning approaches, engineering, and genomic technologies. The genomic expertise of our world-class scientists includes cancer, neurodegenerative and neuropsychiatric disease, genome editing, single-cell and spatially-resolved multiomics, high-resolution imaging, 3-dimensional genome structure, functional genomics, whole genome sequencing, bioinformatics, computational biology, machine learning, genomic data privacy, and molecular diagnostics. Each faculty member has built a robust research program and holds a joint tenure-track appointment at one of our partner institutions. Nygc also has a distinguished group of senior associate faculty, affiliate members, and a scientific advisory board (sab) comprised of world-leaders in genomics and who bring invaluable scientific leadership and mentorship to the center. Our senior leadership team, together with the extensive experience and guidance of our senior faculty and scientific advisory board, empowers the next generation of genomic researchers to pursue groundbreaking discoveries in biomedical research, driving advancements that can transform healthcare and improve patient outcomes. In 2024, nygc scientists published 78 studies in high-impact scientific journals, establishing new insights into the causes and mechanisms of disease, innovative new genomic technologies, and novel computational approaches shared widely with the scientific community to help advance precision medicine. Two of nygc's core faculty members, rahul satija, phd, and neville sanjana, phd, were once again named among the world's most cited researchers on clarivate analytics' 2024 highly cited researchers list for the sixth consecutive year, a testament to their impactful contributions and influence in their respective fields of study. This annual list gathers those in the field who demonstrated significant and broad influence reflected in their publications of multiple highly cited papers over the last decade. The highly cited papers rank in the top 1% by citation for a field or fields and publication year in the web of science. In 2024, nygc expanded its commitment to scientific training with the launch of its early career development program for post-baccalaureates. This program welcomed its first cohort of aspiring researchers with the opportunity to gain hands-on research experience in genomics, computational biology, technology innovation, and clinical genetic testing. Nygc has continued to make significant progress in its core research areas. Noteworthy examples of this progress include: cancer: nygc's signature polyethnic-1000 (p-1000) is a multi-institutional collaborative effort led by drs. Harold varmus and charles sawyers, nygc's cancer group, and leaders from across new york city's cancer research community, leveraging the city's extraordinary diversity to advance cancer genomics and its application in clinical care. Designed to democratize cancer genomics through whole-genome sequencing, bioinformatic analysis, clinical research, and community outreach, p-1000 has created a powerful platform for understanding how different genetic backgrounds influence cancer. This widely recognized framework laid the foundation for team sambai, recipient of the prestigious cancer grand challenge (cgc) award. Led by dr. Melissa davis, nygc associate faculty member; director, institute of translational genomic medicine, morehouse school of medicine; scientific director, international center for the study of breast cancer subtypes; director of health equity, englander institute of precision medicine; and associate professor of cell and developmental biology, weill cornell medicine, team sambai (societal, ancestry, molecula”

“Genomic technology: this year, the nygc technology innovation lab has focused significant efforts on advancing spatial genomics and molecular profiling technologies. Through innovative projects like microst, spatial cut&tag, and the development of the csplotch algorithm, the team is delivering tools that enhance our understanding of gene expression, cellular composition, and tissue-specific gene regulation. These projects are not only expanding the available research toolkit and capabilities in the field, but also revealing new insights into the molecular mechanisms underlying complex biological processes, aging, and disease - insights that may pave the way for future therapeutic breakthroughs. The nygc has built an impressive genomic technology and sequencing infrastructure, enabling high-throughput next-generation sequencing with robust analytics and broad access to cutting-edge technologies to the new york research community. The nygc production sequencing lab has been generating sequencing data for a large number of projects and a diverse set of investigators from throughout the new york city community and beyond, including for major nih grants and for the brain initiative cell atlas network (bican), primarily in collaboration with the allen institute in seattle. The lab has sequenced nearly 200 illumina flow cells (nearly 3 trillion sequencing reads), generating large scale single cell and multiomic data for the atlas. The center remains at the forefront of high-quality sequencing at scale through early and strategic investment in the latest tools and technologies. Clinical laboratory: nygc houses a state-of-the-art clinical diagnostic laboratory that utilizes next-generation sequencing technology to perform advanced tests in genetics and oncology. This lab is foundational to nygc's ability to deliver rapid, high-quality clinical genomic services that are directly shaping patient care. One of nygc's flagship initiatives is the women's genetics center (wgc), launched in partnership with new york-presbyterian hospital and columbia university irving medical center. This collaboration is dedicated to changing women's healthcare through the clinical application of genome sequencing (gs). The wgc is developing affordable, routine gs-based tests for women seeking genetic consultation for pregnancy planning, fetal anomalies, and prenatal genetic testing. The goal is to eventually replace traditional tests, such as karyotyping, chromosomal microarrays, and panel or exome sequencing, with more comprehensive, cost-effective gs solutions. Community: in support of nygc's vision and values, nygc is committed to fostering community and a culture of belonging, shared purpose, and mutual respect. The organization has been working to help employees feel connected to their work and the center's core values, while building a strong sense of community. Our goal is to ensure that every community member feels represented, respected, supported, and treated with dignity, while celebrating their unique backgrounds, talents, and perspectives.”